Travere Therapeutics, Inc. (TVTX)
After hours:
| Previous Close | 8.28 |
| Open | 8.36 |
| Bid | 8.20 x 100 |
| Ask | 8.24 x 200 |
| Day's Range | 7.85 - 8.36 |
| 52 Week Range | 5.12 - 17.57 |
| Volume | |
| Avg. Volume | 1,270,001 |
| Market Cap | 625.78M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.41 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.86 |
Simply Wall St.Shareholders in Travere Therapeutics (NASDAQ:TVTX) are in the red if they invested five years ago
Travere Therapeutics, Inc. ( NASDAQ:TVTX ) shareholders should be happy to see the share price up 21% in the last...
GlobeNewswireTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan a
- GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the National Kidney Foundation (NKF) Spring Clinical Meetings in Long Beach, California, May 14-18, 2024, and the European Renal Association (ERA) Congress i
